Dr BV Ravi Kumar, founder chairman and MD, XCyton Diagnostics
XCyton is a revolutionary molecular biology company founded in 1993 by Dr BV Ravi Kumar. BioSpectrum spoke to Dr Kumar, who is a physician-scientist turned technocrat, spearheading a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs.
How many clinical trials have been conducted using XCyton Diagnostics' Syndrome Evaluation System (SES) and what are the outcomes of these studies?
We have conducted three levels of trials for the Syndrome Evaluation System (SES). The first was the laboratory evaluation in which the clinical specimen obtained from proven cases of various infections were tested along with other infections for which all conventional tests failed to detect any infectious agents. The trial for eye infections was conducted at Sankara Netralaya, Chennai, for acute encephalitis syndrome at National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore and for sepsis at St John's Medical College, Bangalore.
This was followed by a prospective study on the clinical samples in comparison to all the conventional tests. For eye infections, it was conducted at Aravind Eye Hospital, Coimbatore and Prabha Eye Clinic at Bangalore. For acute encephalitis it was done at NIMHANS and for sepsis at Fortis Hospital, Noida.
The third trial was the clinical outcome of the studies, where we tested if the clinical outcome was influenced by using SES as opposed to use of conventional tests. For eye infections it was conducted at Aravind Eye Hospital and for encephalitis and meningitis at KG Hospital, Coimbatore. For sepsis it was done at Fortis Hospital, Noida, HCG, Bangalore and KR Hospital, Bangalore.